Acute renal failure in a patient with epidermolysis bullosa acquisita^*

Abstract:

Epidermolysis bullosa acquisita is a severe autoimmune subepidermal bullous disease. In this report, we described for the first time a patient with epidermolysis bullosa acquisita who developed acute renal failure. There is a possibility that epidermolysis bullosa acquisita and acute renal failure’s pathogenesis shared some common autoimmune pathways. Moreover, acute blood volume reduction may be another cause of prerenal kidney failure. Further studies are needed to verify our hypothesis.

Keywords:
Epidermolysis bullosa acquisita; Methylprednisolone; Methylprednisolone hemisuccinate

INTRODUCTION

Epidermolysis bullosa acquisita (EBA) is a severe autoimmune subepidermal bullous disease, with autoantibodies attached to the cutaneous basement membrane zone (BMZ) of the skin. ¹ EBA was reported to occur along with many systemic diseases, such as systemic lupus erythematosus (SLE), Crohn’s disease, Graves’ disease, and viral infection, with Crohn’s disease being the most frequent. ^2,3 In this report, we described for the first time a patient with EBA who developed acute renal failure (ARF).

CASE REPORT

A 74-year-old Chinese Han man reported a history of pruritus universalis for six months and bullous eruption on the trunk for one month. He was in good health before the onset of the disease, according to yearly physical examinations. He had no chronic disease and was not regularly taking any medicine. Before being admitted to our hospital, he had been treated with oral prednisone 50 mg for six days, but there was no improvement of the skin lesions. Numerous erosions and blisters were observed on the trunk skin, with a mosaic-like distribution, and the Nikolsky sign was negative (Figure 1). The blood count test and liver and renal function tests were normal three days before the hospital visit.

Figure 1
Numerous erosions and blisters on the back

Skin biopsy revealed a subepidermal blister with lymphocytes and eosinophils infiltrating into the superficial layer of the dermis. Perilesional skin direct immunofluorescence (DIF) revealed linear deposition of IgG, IgA, and C3 at the dermo-epidermal junction. Indirect immunofluorescence (IIF) studies on salt-split skin demonstrated deposits of IgG, IgA. and C3 autoantibodies on the dermal side of the dermo-epidermal separation, pemphigoid circulating antibodies were negative (Figure 2). These findings supported the clinical diagnosis of EBA.

Figure 2
Deposits of IgG, IgA, and C3 autoantibodies on the dermal side of the dermo-epidermal separation (X200)

The patient was treated with methylprednisolone at 80 mg per day and ethacridine lactate soaking. After three days of treatment, he showed significant improvement: all lesions began to heal with no new vesicle eruptions. However, acute renal failure (ARF) occurred. The liver and renal function tests showed total protein in serum of 56.5 g/L (normal is 60-83 g/L), in creatinine of 258.0 umol/L (the normal is 45-85 umol/L), in urea of 19.26 mmol/L (the normal is 1.7-8.3 mmol/L), and in uric acid of 560.0 mmol/L (the normal is 214488 mmol/L). The blood count test was normal. His urine volume was no more than 400 ml within 24 hours, and routine urinalysis revealed ERY++++, PRO+. The next day, the patient’s physical condition became worse: total protein in serum was 45.7 g/L; creatinine, 384.9 umol/L; urea, 34.67 mmol/L; and uric acid, 748.0 mmol/L.

The patient was transferred to the nephrology department of Qihe county people’s hospital for further treatment. He was treated with 0.9% NaCl and hydroxyethyl starch (HES) to expand his blood volume, together with intravenous injections of lipid soluble and water soluble vitamins, adenosine triphosphate (ATP), MgCl₂, and KCl. Methylprednisolone, at 80 mg per day, was continued. After two weeks of treatment, the patient’s creatinine was 105.6 umol/L and his urea was 12.23 mmol/L, so the prednisone dose was reduced to 60 mg per day, and no new bullous eruptions occurred. Eight weeks later, his creatinine level was 112.1 umol/L and urea, 10.23 mmol/L, so the prednisone dose was reduced to 50 mg per day, and very few erythemas were seen.

DISCUSSION

In this case, ARF occurred shortly after the development of EBA, and rapidly recovered with symptomatic treatment. Although many autoimmune diseases could simultaneously develop in the same patient, it is still unclear why these two diseases occurred almost simultaneously in our patient and whether their pathogeneses are related. It is important to investigate these relationships and provide more effective treatment for EBA in order to better prevent the occurrence of ARF.

EBA is an autoimmune disease, which is associated with a systemic disease in 10-50% of the patients. ⁴ Many different abnormal antibodies and alexins, including IgG, IgA, IgE, IgM, C3, and C4, have been found in the skin and other tissues of EBA patients. ^5-8 Patrick Macken et al. reported a case of crescentic glomerulonephritis in a patient with EBA in 1995, which suggested an autoimmune relationship between EBA and kidney disease. ⁹ Therefore, it is possible that EBA and ARF pathogeneses share common autoimmune pathways. In addition, due to the large amount of exudate on the skin lesions, patients with severe EBA suffer from acute blood volume reduction, which may be another cause of pre-renal failure. Further studies, such as renal biopsy, are needed to verify our hypothesis. Nevertheless, many reasons could lead to ARF, such as decreased renal perfusion due to volume depletion, acute heart failure, acute hepatic failure, acute tubular necrosis, obstruction of urinary flow, and prostatic hypertrophy. ^10,11 Urinary tract obstruction and infection could be excluded according to clinical manifestations and laboratory examination. The gold standard of ARF diagnosis is the biopsy, but it was declined by the patient and relatives. Therefore, we could not confirm the exact etiology of ARF in this case.

• *
  Work performed at the Shandong Provincial Hospital for Skin Diseases, Shandong University, Shandong, China.
• Financial support: None

REFERENCES

• ¹
  Chen M, Kim GH, Prakash L, Woodley DT. Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen. Autoimmunity. 2012;45:91-101.
• ²
  Gupta R, Woodley DT, Chen M. Epidermolysis bullosa acquisita. Clin Dermatol. 2012;30:60-9.
• ³
  Piccolo V, Moscarella E, Errico M, Russo T, Tripodi Cutrì F, Ametrano O, et al. Could cytomegalovirus infection play a causative role in epidermolysis bullosa acquisita? Eur J Dermatol. 2011;21:607-8.
• ⁴
  Modiano P, Prost C, Barbaud A, Vignaud JM, Grignon Y, Schmutz JL, et al. Epidermolysis bullosa acquisita and benign schwannoma. J Am Acad Dermatol. 1996;35:472-3.
• ⁵
  Bauer JW, Schaeppi H, Metze D, Muss W, Pohla-Gubo G, Hametner R, et al. Ocular involvement in IgA-epidermolysis bullosa acquisita. Br J Dermatol. 1999;141:887-92.
• ⁶
  Miyake H, Morishima Y, Komai R, Hashimoto T, Kishimoto S. Epidermolysis bullosa acquisita: Correlation of IgE levels with disease activity under successful betamethasone/dapsone combination therapy. Acta Derm Venereol. 2001;81:429.
• ⁷
  Suchniak JM, Diaz LA, Lin MS, Fairley JA. IgM-mediated epidermolysis bullosa acquisita. Arch Dermatol. 2002;138:1385-6.
• ⁸
  Tokuda Y, Amagai M, Yaoita H, Kawachi S, Ito T, Matsuyama I, et al. A case of an inflammatory variant of epidermolysis bullosa acquisita: chronic bullous dermatosis associated with nonscarring mucosal blisters and circulating IgG antitype-9. VII-collagen antibody. Dermatology. 1998;197:58-61.
• ⁹
  Macken P, Moorthy AV. Crescentic glomerulonephritis in a patient with epidermolysis bullosa acquisita. Nephron. 1995;70:120.
• ¹⁰
  Rahman M, Shad F, Smith MC. Acute kidney injury: a guide to diagnosis and management. Am Fam Physician. 2012 Oct 1;86(7):631-9.
• ¹¹
  Hilton R. Acute renal failure. BMJ. 2006 Oct 14;333:786-90.

Publication Dates

• Publication in this collection
  2017

History

• Received
  03 Mar 2016
• Accepted
  27 Apr 2016